دورية أكاديمية
Polycystic Kidney Disease Diet: What is Known and What is Safe.
| العنوان: | Polycystic Kidney Disease Diet: What is Known and What is Safe. |
|---|---|
| المؤلفون: | Chebib FT; Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida., Nowak KL; Division of Renal Diseases and Hypertension, Polycystic Kidney Disease Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Chonchol MB; Division of Renal Diseases and Hypertension, Polycystic Kidney Disease Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Bing K; University of Colorado Anschutz Medical Campus, Aurora, Colorado., Ghanem A; Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida., Rahbari-Oskoui FF; Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia., Dahl NK; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota., Mrug M; Division of Nephrology, Department of Medicine, Department of Veterans Affairs Medical Center, University of Alabama at Birmingham, Birmingham, Alabama. |
| المصدر: | Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2024 May 01; Vol. 19 (5), pp. 664-682. Date of Electronic Publication: 2023 Sep 20. |
| نوع المنشور: | Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101271570 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-905X (Electronic) Linking ISSN: 15559041 NLM ISO Abbreviation: Clin J Am Soc Nephrol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Hagerstown, MD : Wolters Kluwer Health Original Publication: Washington, D.C. : American Society of Nephrology, c2005- |
| مواضيع طبية MeSH: | Polycystic Kidney, Autosomal Dominant*/diet therapy , Polycystic Kidney, Autosomal Dominant*/complications , Polycystic Kidney, Autosomal Dominant*/physiopathology , Polycystic Kidney, Autosomal Dominant*/therapy , Caloric Restriction* , Diet, Ketogenic*/adverse effects, Humans ; Fasting ; Animals |
| مستخلص: | Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by kidney cyst formation and progressive kidney function loss. Dietary interventions such as caloric restriction, intermittent fasting, and ketogenic diet have recently emerged as potential strategies to induce metabolic reprogramming and slow ADPKD progression. We review the available evidence supporting the efficacy and safety of these interventions in ADPKD. Dietary interventions show promise in managing ADPKD by improving metabolic health and reducing oxidative stress. However, while preclinical studies have shown favorable outcomes, limited clinical evidence supports their effectiveness. In addition, the long-term consequences of these dietary interventions, including their effect on adverse events in patients with ADPKD, remain uncertain. To optimize ADPKD management, patients are advised to follow a dietary regimen that aims to achieve or maintain an ideal body weight and includes high fluid intake, low sodium, and limited concentrated sweets. Caloric restriction seems particularly beneficial for patients with overweight or obesity because it promotes weight loss and improves metabolic parameters. Supplementation with curcumin, ginkgolide B, saponins, vitamin E, niacinamide, or triptolide has demonstrated uncertain clinical benefit in patients with ADPKD. Notably, β -hydroxybutyrate supplements have shown promise in animal models; however, their safety and efficacy in ADPKD require further evaluation through well-designed clinical trials. Therefore, the use of these supplements is not currently recommended for patients with ADPKD. In summary, dietary interventions such as caloric restriction, intermittent fasting, and ketogenic diet hold promise in ADPKD management by enhancing metabolic health. However, extensive clinical research is necessary to establish their effectiveness and long-term effects. Adhering to personalized dietary guidelines, including weight management and specific nutritional restrictions, can contribute to optimal ADPKD management. Future research should prioritize well-designed clinical trials to determine the benefits and safety of dietary interventions and supplementation in ADPKD. (Copyright © 2023 by the American Society of Nephrology.) |
| References: | Nat Rev Nephrol. 2013 Apr;9(4):223-39. (PMID: 23438973) Nephrol Dial Transplant. 2008 Sep;23(9):2847-52. (PMID: 18372389) Clin J Am Soc Nephrol. 2009 Oct;4(10):1565-74. (PMID: 19808241) Kidney Int. 2020 Oct;98(4):989-998. (PMID: 32534051) Clin Kidney J. 2021 Sep 13;15(6):1079-1092. (PMID: 35664270) J Am Soc Nephrol. 2002 Nov;13(11):2723-9. (PMID: 12397042) Clin J Am Soc Nephrol. 2022 Feb;17(2):240-250. (PMID: 34907021) Kidney Int. 2003 Apr;63(4):1230-9. (PMID: 12631339) NEJM Evid. 2022 Jan;1(1):EVIDoa2100021. (PMID: 38319283) Kidney Int. 2000 Jan;57(1):159-66. (PMID: 10620197) Nephrol Dial Transplant. 2022 Apr 25;37(5):825-839. (PMID: 35134221) J Am Soc Nephrol. 2018 Feb;29(2):571-578. (PMID: 29118087) Res Commun Chem Pathol Pharmacol. 1990 Sep;69(3):335-51. (PMID: 2236900) Diabetes Care. 2014 Feb;37(2):483-7. (PMID: 24062331) Braz J Med Biol Res. 2012 Sep;45(9):834-40. (PMID: 22801417) Am J Kidney Dis. 1998 Jan;31(1):55-61. (PMID: 9428452) J Am Soc Nephrol. 1995 Jun;5(12):2037-47. (PMID: 7579052) Am J Kidney Dis. 2016 Dec;68(6):882-891. (PMID: 27663039) Clin J Am Soc Nephrol. 2011 Mar;6(3):640-7. (PMID: 21088290) J Nutr. 2003 Jan;133(1):180-6. (PMID: 12514287) Nutrients. 2019 Oct 14;11(10):. (PMID: 31614992) Am J Physiol. 1998 Mar;274(3):F541-9. (PMID: 9530270) Curr Hypertens Rev. 2021;17(3):228-237. (PMID: 32807060) Nat Commun. 2023 Mar 30;14(1):1790. (PMID: 36997516) Am J Kidney Dis. 1998 Apr;31(4):687-93. (PMID: 9531187) Curr Drug Metab. 2019;20(2):147-154. (PMID: 30112986) Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915. (PMID: 34117082) Lancet. 2019 Mar 2;393(10174):919-935. (PMID: 30819518) Molecules. 2018 Aug 03;23(8):. (PMID: 30081476) Kidney Int Rep. 2020 Jun 10;5(8):1271-1279. (PMID: 32775826) iScience. 2021 Dec 27;25(1):103697. (PMID: 35059607) Front Nutr. 2021 Jul 16;8:702802. (PMID: 34336911) J Am Soc Nephrol. 2016 May;27(5):1437-47. (PMID: 26538633) Kidney Int. 2008 Jan;73(1):19-33. (PMID: 17928825) Life Sci. 2022 Jan 15;289:120227. (PMID: 34921866) Nutrients. 2021 May 13;13(5):. (PMID: 34068325) PLoS One. 2016 May 23;11(5):e0155790. (PMID: 27213553) Nat Rev Nephrol. 2018 Nov;14(11):678-687. (PMID: 30120380) Mol Med Rep. 2021 Mar;23(3):. (PMID: 33495815) Kidney Int. 2020 Oct;98(4):831-834. (PMID: 32998813) Nutrients. 2022 Jan 31;14(3):. (PMID: 35276989) Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1765-1776. (PMID: 30049849) Nutrients. 2021 Jan 14;13(1):. (PMID: 33466692) J Am Soc Nephrol. 2018 Jan;29(1):13-23. (PMID: 29038287) J Clin Invest. 2019 Jul 30;129(10):4506-4522. (PMID: 31361604) Kidney Int. 1999 Feb;55(2):417-23. (PMID: 9987066) Lipids. 2004 Mar;39(3):207-14. (PMID: 15233398) J Nutr. 2000 Sep;130(9):2356-60. (PMID: 10958835) Nat Rev Endocrinol. 2022 May;18(5):309-321. (PMID: 35194176) J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. (PMID: 30228150) Cell Metab. 2014 Feb 4;19(2):181-92. (PMID: 24440038) Nutrition. 2020 Mar;71:110594. (PMID: 31790890) Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F726-F731. (PMID: 26764208) Nephron Exp Nephrol. 2007;106(4):e122-8. (PMID: 17622740) Childs Nerv Syst. 2020 Jun;36(6):1099-1109. (PMID: 32173786) J Nephrol. 2018 Feb;31(1):87-94. (PMID: 28386880) Kidney Int. 2017 Feb;91(2):493-500. (PMID: 27993381) Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202. (PMID: 21345977) Am J Physiol Renal Physiol. 2013 Aug 15;305(4):F574-82. (PMID: 23698116) Trends Cardiovasc Med. 2022 Oct;32(7):399-405. (PMID: 34384881) Clin J Am Soc Nephrol. 2020 Apr 7;15(4):577-584. (PMID: 32086281) J Am Soc Nephrol. 2008 Sep;19(9):1659-62. (PMID: 18650476) Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F35-F42. (PMID: 31682174) Nutrients. 2019 Jul 12;11(7):. (PMID: 31336917) Am J Clin Nutr. 2017 Apr;105(4):913-927. (PMID: 28228420) Am J Kidney Dis. 2001 Nov;38(5):1089-95. (PMID: 11684564) Clin J Am Soc Nephrol. 2019 May 7;14(5):682-691. (PMID: 31023928) N Engl J Med. 2022 Apr 21;386(16):1495-1504. (PMID: 35443107) J Ren Nutr. 2001 Oct;11(4):183-93. (PMID: 11679998) Cell Metab. 2014 Dec 2;20(6):991-1005. (PMID: 25470547) J Cardiovasc Dev Dis. 2021 Oct 29;8(11):. (PMID: 34821697) Am J Kidney Dis. 2016 May;67(5):792-810. (PMID: 26530876) Nephrol Dial Transplant. 2013 Feb;28(2):380-5. (PMID: 23222419) Nephrol Dial Transplant. 2023 Jun 30;38(7):1623-1635. (PMID: 36423335) Sci Signal. 2019 May 07;12(580):. (PMID: 31064883) BMC Med. 2021 Dec 9;19(1):313. (PMID: 34879839) Cell Metab. 2019 Dec 3;30(6):1007-1023.e5. (PMID: 31631001) BMC Nephrol. 2018 Dec 27;19(1):378. (PMID: 30591038) |
| معلومات مُعتمدة: | P30 DK048520 United States DK NIDDK NIH HHS; R01 DK129259 United States DK NIDDK NIH HHS |
| سلسلة جزيئية: | ClinicalTrials.gov NCT04907799; NCT04534985 |
| تواريخ الأحداث: | Date Created: 20230920 Date Completed: 20240508 Latest Revision: 20240629 |
| رمز التحديث: | 20240629 |
| مُعرف محوري في PubMed: | PMC11108253 |
| DOI: | 10.2215/CJN.0000000000000326 |
| PMID: | 37729939 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!